Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer | Zendy

Sunil Verma | Zendy; David Miles | Zendy; Luca Gianni | Zendy; Ian E. Krop | Zendy; Manfred Welslau | Zendy; José Baselga | Zendy; Mark D. Pegram | Zendy; DoYoun Oh | Zendy; Véronique Dièras | Zendy; Ellie Guardino | Zendy; Fang Ting Liang | Zendy; Michael W. Lu | Zendy; Steven R. Olsen | Zendy; Kim T. Blackwell | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer

Author(s) -

Sunil Verma,

David Miles,

Luca Gianni,

Ian E. Krop,

Manfred Welslau,

José Baselga,

Mark D. Pegram,

DoYoun Oh,

Véronique Dièras,

Ellie Guardino,

Fang Ting Liang,

Michael W. Lu,

Steven R. Olsen,

Kim T. Blackwell

Publication year - 2012

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1209124

Subject(s) - trastuzumab emtansine , trastuzumab , antibody drug conjugate , medicine , cytotoxic t cell , metastatic breast cancer , conjugate , breast cancer , oncology , antibody , linker , cancer research , cancer , monoclonal antibody , pharmacology , immunology , in vitro , biology , mathematical analysis , biochemistry , mathematics , computer science , operating system

Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate incorporating the human epidermal growth factor receptor 2 (HER2)-targeted antitumor properties of trastuzumab with the cytotoxic activity of the microtubule-inhibitory agent DM1. The antibody and the cytotoxic agent are conjugated by means of a stable linker.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research